Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.40 |
| ▸ | NNMT | P40261 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24363767 | 1.00 | GPR35 (0.40) | GPR35NNMTPRMT5WDR77TYK2 | |
| SCHEMBL25955826 | 0.83 | GPR35 (0.41) | GPR35NNMTTYK2PTPN1PTPN11 | |
| SCHEMBL30469631 | 0.81 | NNMT (0.40) | GPR35NNMTKDM4EPDE4BPTPN11 | |
| SCHEMBL29347066 | 0.81 | GPR35 (0.37) | GPR35NNMTPDE4APDE4BPDE4C | |
| SCHEMBL24363780 | 0.81 | NNMT (0.40) | GPR35NNMTKDM4EPDE4BPTPN11 | |
| SCHEMBL30471174 | 0.80 | PRMT5 (0.49) | GPR35PRMT5WDR77PTPN1PTPN11 | |
| SCHEMBL24363962 | 0.80 | PRMT5 (0.49) | GPR35PRMT5WDR77PTPN1PTPN11 | |
| SCHEMBL24364756 | 0.78 | GPR35 (0.45) | GPR35PRMT5WDR77KDM4E | |
| SCHEMBL24363766 | 0.76 | MAPT (0.39) | GPR35KDM4EKMT2A | |
| SCHEMBL30470707 | 0.76 | MAPT (0.39) | GPR35KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | GPR35 2110/4885NNMT 2205/4885PRMT5 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.